Porter Derrell 4
4 · Atara Biotherapeutics, Inc. · Filed May 16, 2018
Insider Transaction Report
Form 4
Porter Derrell
SVP, Head of Global Commercial
Transactions
- Exercise/Conversion
Common Stock
2018-05-15$14.30/sh+16,334$233,576→ 28,834 total - Sale
Common Stock
2018-05-15$45.02/sh−16,334$735,357→ 12,500 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-05-15−16,334→ 113,666 totalExercise: $14.30Exp: 2024-05-10→ Common Stock (16,334 underlying)
Footnotes (3)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $45.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F3]25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.